Disease Activity-Guided Dosing Safe, Effective for up to 10 Years in Rheumatoid ArthritisJune 6th 2023
Noortje van Herwaarden, MD, PhD, discusses the results of a 10-year follow-up from the DRESS study and how it informs use of disease activity-guided dose optimization in treatment of rheumatoid arthritis.
SGLT2 Inhibitors Could Lower Risk of Recurrent Gout Flares in People with DiabetesJune 4th 2023
A new-user, active comparator cohort study from EULAR 2023 suggests use of SGLT2 inhibitors could lower risk of recurrent gout flares in people with type 2 diabetes and gout compared to use of DPP-4 inhibitors.
Pegloticase Use Could Contribute to Bone Remodeling in Gout PatientsJune 2nd 2023
An analysis of DECT imaging from the MIRROR trial is providing clinicians with insight into the potential for urate crystal resolution and bone remodeling with pegloticase plus methotrexate in patients with uncontrolled gout.
For People with Diabetes, Starting an SGLT2 Inhibitor Could Lower Gout RiskJune 2nd 2023
An analysis of more than 20,000 people with type 2 diabetes suggests initiating therapy with an SGLT2 inhibitor, as a second-line treatment to metformin, was associated with a lower risk of developing gout relative to other second-line therapies.
Pegloticase Use and Quality of Life in Uncontrolled Gout, with Brian LaMoreaux, MDJune 1st 2023
Brian LaMoreaux, MD, discusses data from an analysis of the MIRROR trial examining the impact of pegloticase plus methotrexate on patient-reported outcomes and quality of life measures among patients with uncontrolled gout.
Risankizumab Provides Durable Quality of Life Improvements out to 100 Weeks in Psoriatic ArthritisJune 1st 2023
An analysis of 100 week data from the KEEPsAKE 1 and 2 trials presented at EULAR 2023 offers insight into the long-term effects of risankizumab use in people with psoriatic arthritis.
Nick Stucky, MD, Phd: Implications for Media Influence on Minoxidil Prescribing Rates
During this interview segment, Stucky continued on his team's findings on a newspaper article’s association with increased prescribing rates of oral minoxidil, explaining the study’s limitations and implications.
Ursula Schmidt-Erfurth, MD: Therapeutic Effect of Pegcetacoplan on GA Disease ActivityMay 3rd 2023
At ARVO 2023, Schmidt-Erfurth discusses new insights regarding disease activity in GA, observing reductions in both RPE and photoreceptor degeneration after intravitreal pegcetacoplan therapy in the OAKS and DERBY trials.
Andres Emanuelli, MD: Analysis of the Port Delivery System in the Phase 3 Pavilion TrialMay 3rd 2023
At ARVO 2023, Emanuelli discusses the primary analysis results of the phase 3 Pavilion trial evaluating the PDS with ranibizumab in patients with diabetic retinopathy without center-involved diabetic macular edema.
Carl Danzig, MD: Analysis of GATHER Trials Connects GA Growth with Vision LossApril 24th 2023
In an interview at ARVO 2023, Danzig discusses the post-hoc analysis from the GATHER trials, showing that a reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced GA growth.
Caroline Baumal, MD: Marking a New Treatment Era for GA with PegcetacoplanApril 24th 2023
At ARVO 2023, Caroline Baumal, MD, chief medical officer of Apellis Pharmaceuticals, discussed new phase 3 functional analyses of pegcetacoplan injection, the future of the GA treatment landscape, and the next unmet need in ophthalmology.
New Insight: A Look at Avacincaptad Pegol with Pravin Dugel, MDApril 23rd 2023
As part of our ARVO 2023 coverage, Dr. Sheth sat down with Pravin Dugel, MD, President of Iveric Bio to discuss avacincaptad pegol for geographic atrophy and a look back at Dr. Dugel's career and his transition into industry.
Ravi Kalhan, MD, MS: Defining Intermediary Respiratory PhenotypesApril 11th 2023
On the latest Lungcast, Kalhan reviewed a 2018 paper he and colleagues penned on the need to establish phenotypes of chronic lung disease progression—such as what cardiology has done with LDL-C for heart attacks.